These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30992657)

  • 1. Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity.
    Pepose JS; Qazi MA; Devries DK
    Clin Ophthalmol; 2019; 13():571-579. PubMed ID: 30992657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review.
    Atallah RT; Castanos MV; Najac R; Donnenfeld E
    Clin Ophthalmol; 2019; 13():1033-1037. PubMed ID: 31354236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
    Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
    JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age Associations with Dry Eye Clinical Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study.
    Zhao M; Yu Y; Ying GS; Asbell PA; Bunya VY;
    Ophthalmol Sci; 2023 Jun; 3(2):100270. PubMed ID: 36846104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.
    Holland EJ; Whitley WO; Sall K; Lane SS; Raychaudhuri A; Zhang SY; Shojaei A
    Curr Med Res Opin; 2016 Oct; 32(10):1759-1765. PubMed ID: 27388660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Evaluation of Matrix Metalloproteinase-9 Immunoassay and Tear Osmolarity Measurement for Diagnosing Severity of Dry Eye Disease.
    Choi M; Park YM; Ko BY
    Korean J Ophthalmol; 2023 Oct; 37(5):409-416. PubMed ID: 37621090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Dry Eye Disease Among Individuals Scheduled for Cataract Surgery in a Norwegian Cataract Clinic.
    Graae Jensen P; Gundersen M; Nilsen C; Gundersen KG; Potvin R; Gazerani P; Chen X; Utheim TP; Utheim ØA
    Clin Ophthalmol; 2023; 17():1233-1243. PubMed ID: 37138823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Analysis of Tear Cytokine Ratios in Association with Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management (DREAM) Study.
    Zhao CS; Chen Y; Yu Y; Ying GS; Asbell PA;
    Curr Eye Res; 2024 Sep; ():1-8. PubMed ID: 39267294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases.
    Versura P; Profazio V; Campos EC
    Curr Eye Res; 2010 Jul; 35(7):553-64. PubMed ID: 20597641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients.
    Schargus M; Ivanova S; Kakkassery V; Dick HB; Joachim S
    Cornea; 2015 Jul; 34(7):739-44. PubMed ID: 25909238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Patients With Dry Eye Disease Associated With Ocular Graft-Versus-Host Disease.
    Wong CW; Le HL; Gombos DS; Yee RW
    Cureus; 2024 Aug; 16(8):e66437. PubMed ID: 39246931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Tear Osmolarity With Signs and Symptoms of Dry Eye Disease in the Dry Eye Assessment and Management (DREAM) Study.
    Greiner JV; Ying GS; Pistilli M; Maguire MG; Asbell PA;
    Invest Ophthalmol Vis Sci; 2023 Jan; 64(1):5. PubMed ID: 36626176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?
    Amparo F; Jin Y; Hamrah P; Schaumberg DA; Dana R
    Am J Ophthalmol; 2014 Jan; 157(1):69-77.e2. PubMed ID: 24060433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra
    Hovanesian JA; Nichols KK; Jackson M; Katz J; Chan A; Glassberg MB; Sloesen B; Korves C; Nguyen C; Syntosi A
    Clin Ophthalmol; 2021; 15():1041-1054. PubMed ID: 33727786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.
    Sullivan BD; Crews LA; Sönmez B; de la Paz MF; Comert E; Charoenrook V; de Araujo AL; Pepose JS; Berg MS; Kosheleff VP; Lemp MA
    Cornea; 2012 Sep; 31(9):1000-8. PubMed ID: 22475641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Nasal Tear Osmolarity on Ocular Symptoms Related to Dry Eye Disease.
    Yi HC; Lee YP; Shin YJ
    Am J Ophthalmol; 2018 May; 189():71-76. PubMed ID: 29470972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.